Atrial fibrillation health risks and management

Atrial fibrillation, a common cardiac arrhythmia characterized by irregular and rapid heartbeats, is identified as a significant risk factor for stroke and heart failure. Medical reports indicate that the condition can be “silent,” meaning patients may experience no noticeable symptoms, which increases the danger of undiagnosed blood clots.

Common symptoms include palpitations, fatigue, dizziness, chest pain, and shortness of breath. The risk of the condition increases significantly with age; while it affects 2-3% of the general population, prevalence can reach 15-20% in individuals in their 80s. Experts note that in some cases, a stroke may serve as the first clinical sign of the disorder.

In Greece, the condition affects approximately 200,000 patients. Cardiology experts, such as Prof. Dr. Dursun Aras, note that this arrhythmia is responsible for approximately one-fifth of all strokes. In Germany, it is estimated to cause 20 to 30 percent of all ischemic strokes and can lead to heart failure in more than one-third of affected patients. In Germany, up to 50 percent of the 1.6 million patients living with the condition may experience no noticeable symptoms.

Neurologists warn that strokes are not limited to the elderly, as younger individuals may misinterpret symptoms like sudden paralysis or speech disturbances as migraines. Experts recommend the FAST rule—checking for facial drooping, arm weakness, and speech difficulties—to identify a stroke and ensure immediate medical attention.

Management focuses on reducing thrombophilic risk through oral anticoagulants and managing symptoms. Diagnosis typically involves an electrocardiogram (ECG) or a 24-hour Holter monitor. Recent advancements in medical technology have improved the safety and effectiveness of invasive procedures compared to traditional antiarrhythmic drugs.